Rani Deepa Selvi, Kasala Apoorva, Dhandapany Perundurai S, Muthusami Uthiralingam, Kunnoth Sreejith, Rathinavel Andiappan, Ayapati Dharma Rakshak, Thangaraj Kumarasamy
Department of Population and Medical Genomics, CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India.
Department of Cardiovascular Biology and Medicine, Institute for Stem Cell Science and Regenerative Medicine, Bangalore, Karnataka, India.
Pharmgenomics Pers Med. 2023 Sep 20;16:883-893. doi: 10.2147/PGPM.S407179. eCollection 2023.
Mutations in Myosin Binding Protein C () are one of the most frequent causes of cardiomyopathies in the world, but not much data are available in India.
We carried out targeted direct sequencing of in 115 hypertrophic (HCM) and 127 dilated (DCM) cardiomyopathies against 197 ethnically matched healthy controls from India.
We detected 34 single nucleotide variations in , of which 19 were novel. We found a splice site mutation [(IVS6+2T) T>G] and 16 missense mutations in Indian cardiomyopathies [5 in HCM; E258K, T262S, H287L, R408M, V483A: 4 in DCM; T146N, V321L, A392T, E393K and 7 in both HCM and DCM; L104M, V158M, S236G, R272C, T290A, G522E, A626V], but those were absent in 197 normal healthy controls. Interestingly, we found 7 out of 16 missense mutations (V158M, E258K, R272C, A392T, V483A, G522E, and A626V) in were altering the evolutionarily conserved native amino acids, accounted for 8.7% and 6.3% in HCM and DCM, respectively. The bioinformatic tools predicted that those 7 missense mutations were pathogenic. Moreover, the co-segregation of those 7 mutations in families further confirmed their pathogenicity. Remarkably, we also identified compound mutations within the gene of 6 cardiomyopathy patients (5%) with more severe disease phenotype; of which, 3 were HCM (2.6%) [(1. K244K + E258K + (IVS6+2T) T>G); (2. L104M + G522E + A626V); (3. P186P + G522E + A626V]; and 3 were DCM (2.4%) [(1. 5'UTR + A392T; 2. V158M+G522E; and 3.V158M + T262T + A626V].
The present comprehensive study on has revealed both single and compound mutations in and their association with disease in Indian Population with Cardiomyopathies. Our findings may perhaps help in initiating diagnostic strategies and eventually recognizing the targets for therapeutic interventions.
肌球蛋白结合蛋白C()突变是全球心肌病最常见的病因之一,但印度的相关数据较少。
我们对115例肥厚型心肌病(HCM)和127例扩张型心肌病(DCM)进行了靶向直接测序,并与197名来自印度、种族匹配的健康对照进行比较。
我们在中检测到34个单核苷酸变异,其中19个是新发现的。我们在印度心肌病患者中发现了一个剪接位点突变[(IVS6 + 2T)T>G]和16个错义突变[5个在HCM中;E258K、T262S、H287L、R408M、V483A:4个在DCM中;T146N、V321L、A392T、E393K,7个在HCM和DCM中均有;L104M、V158M、S236G、R272C、T290A、G522E、A626V],但在197名正常健康对照中未发现。有趣的是,我们发现16个错义突变中有7个(V158M、E258K、R272C、A392T、V483A、G522E和A626V)改变了进化上保守的天然氨基酸,在HCM和DCM中分别占8.7%和6.3%。生物信息学工具预测这7个错义突变具有致病性。此外,这些突变在家族中的共分离进一步证实了它们的致病性。值得注意的是,我们还在6例(5%)心肌病患者的基因中鉴定出复合突变;这些患者具有更严重的疾病表型;其中,3例为HCM(2.6%)[(1. K244K + E258K + (IVS6 + 2T)T>G);(2. L104M + G522E + A626V);(3. P186P + G522E + A626V];3例为DCM(2.4%)[(1. 5'UTR + A392T;2. V158M + G522E;3. V158M + T262T + A626V]。
目前关于的综合研究揭示了基因中的单突变和复合突变及其与印度心肌病患者疾病的关联。我们的发现可能有助于启动诊断策略,并最终确定治疗干预的靶点。